Skip to contentpdufa.bio

Vonaprument (ARCHER II, geographic atrophy)

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

Vonaprument (ARCHER II, geographic atrophy) is an Annexon, Inc. program. Its next catalyst is a Readout in Q4 2026.

ANNX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Annexon, Inc. (ANNX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026ANNX

Specialist biotech funds holding ANNX, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Redmile Group14,278,075$60.4 millionfiled November 16, 2026
BVF Inc.8,278,164$35.0 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Vonaprument (ARCHER II, geographic atrophy)'s next FDA decision or readout?

The next tracked catalyst for Vonaprument (ARCHER II, geographic atrophy) is a Readout in Q4 2026.

What happened at Vonaprument (ARCHER II, geographic atrophy)'s most recent FDA decision?

No FDA decision for Vonaprument (ARCHER II, geographic atrophy) is in our archive yet.

Who makes Vonaprument (ARCHER II, geographic atrophy)?

Annexon, Inc. (ANNX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.